ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Abatement of acrylonitrile-induced gastric injury by 2-Methoxyestradiol through inhibition of TLR4/MYD88/phospho-p38 MAPK axis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acrylonitrile (ACN) is a widely used industrial chemical. It has a wide range of toxicities, including gastric mucosal damage. 2-Methoxyestradiol (2ME) is one of the estrogen metabolites with a plethora of beneficial pharmacological activities. This study aimed to evaluate the possible preventive effects of 2ME against ACN-induced gastric injury in rats. 2ME was injected intraperitoneally into rats at two dose levels (1 and 5 mg/kg) prior to a single oral dose of ACN (30 mg/kg). 2ME obviously prevented histopathological alteration in gastric tissues. 2ME prevented ACN-induced oxidative damage as shown by preventing malondialdehyde (MDA) accumulation and superoxide dismutase (SOD) and catalase (CAT) exhaustion. Also, it prevented ACN-induced increase in the immuno-expression of cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and nuclear factor kappa B (NF-κB). 2ME modulated ACN-induced changes in B-cell lymphoma 2-associated X protein (Bax) and B-cell lymphoma 2 (Bcl-2) expression, opposing apoptotic death of gastric tissues. Finally, 2ME inhibited ACN-induced enhancement of toll-like receptor 4 (TLR4), myeloid differentiation primary response protein 88 (MYD88), and phosphorylated p38 mitogen-activated protein kinase (phospho-p38 MAPK) immuno-expression. Conclusively, 2ME ameliorates ACN-induced gastric injury. This protective effect may be associated with the antioxidant, anti-inflammatory, and anti-apoptotic properties of 2ME, in addition to a potential modulation of the TLR4/MYD88/phospho-p38 MAPK signaling pathway.
Indexed as
Identifiers
41765947What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.